"Diphosphonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
| Descriptor ID |
D004164
|
| MeSH Number(s) |
D02.705.429.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diphosphonates".
Below are MeSH descriptors whose meaning is more specific than "Diphosphonates".
This graph shows the total number of publications written about "Diphosphonates" by people in this website by year, and whether "Diphosphonates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 2 | 5 |
| 2003 | 5 | 0 | 5 |
| 2004 | 11 | 1 | 12 |
| 2005 | 7 | 3 | 10 |
| 2006 | 5 | 2 | 7 |
| 2007 | 9 | 4 | 13 |
| 2008 | 14 | 4 | 18 |
| 2009 | 3 | 2 | 5 |
| 2010 | 13 | 4 | 17 |
| 2011 | 8 | 4 | 12 |
| 2012 | 11 | 4 | 15 |
| 2013 | 12 | 1 | 13 |
| 2014 | 5 | 3 | 8 |
| 2015 | 4 | 2 | 6 |
| 2016 | 2 | 4 | 6 |
| 2017 | 3 | 2 | 5 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 3 | 4 |
| 2020 | 3 | 2 | 5 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphosphonates" by people in Profiles.
-
The Case for Bisphosphonate Use in Astronauts Flying Long-Duration Missions. Cells. 2024 Aug 13; 13(16).
-
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis. Clin Breast Cancer. 2023 12; 23(8):e515-e522.
-
Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023 06 16; 108(7):1787-1796.
-
Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023 02 15; 108(3):507-528.
-
Early identification of a 12-bp tandem duplication in TNFRSF11A encoding receptor activator of nuclear factor-kappa B (RANK): Clinical characterization and response to bisphosphonate therapy. Bone. 2023 05; 170:116698.
-
A multicenter study to evaluate pain characteristics in osteogenesis imperfecta. Am J Med Genet A. 2023 Jan; 191(1):160-172.
-
Craniofacial and dental phenotype of two girls with osteogenesis imperfecta due to mutations in CRTAP. Bone. 2022 11; 164:116516.
-
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocr Pract. 2022 Oct; 28(10):1078-1085.
-
Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021 12; 50(4):721-728.
-
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Aug 01; 7(8):1149-1157.